drugset / Trial / NCT01406717

Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus

NCT01406717 ↗

Phase 3 Completed 360 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

SPIL1033 resembles a gut hormone, which increases the insulin secretion, thus helps in reducing blood glucose levels. The purpose of study is to establish safety and efficacy of SPIL1033

Timeline

Start
2013-03-01
Primary completion
2015-11-04
Completion
2015-11-04

Drugs

EvaluationDrugModalityDoseRoute
Subject SPIL1033 Unknown 10 ug Subcutaneous